SCHEMBL26566973

SCHEMBL26566973

CS(=O)(=O)Cc1cc(C(=O)O)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.51
GABRD O14764 1/20 0.51
GABRA1 P14867 1/20 0.51
GABRB1 P18505 1/20 0.51
GABRG2 P18507 1/20 0.51
GABRB3 P28472 1/20 0.51
GABRA5 P31644 1/20 0.51
GABRA3 P34903 1/20 0.51
GABRA2 P47869 1/20 0.51
GABRB2 P47870 1/20 0.51
GABRA4 P48169 1/20 0.51
GABRE P78334 1/20 0.51
GABRA6 Q16445 1/20 0.51
GABRG1 Q8N1C3 1/20 0.51
GABRG3 Q99928 1/20 0.51
GABRQ Q9UN88 1/20 0.51
KDM4D Q6B0I6 3/20 0.50
KDM5B Q9UGL1 8/20 0.49
KDM5C P41229 6/20 0.49
KDM4C Q9H3R0 6/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14993600 0.85 MBOAT4 (0.45) GABRPGABRDGABRA1GABRB1GABRG2
Lithium Ion SCHEMBL29700415 0.84 KDM5C (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29700435 0.83 KDM4E (0.51) KDM5BKDM5CKDM4CKDM6BKDM5A
SCHEMBL346941 0.83 KDM4E (0.51) KDM5BKDM5CKDM4CKDM6BKDM5A
SCHEMBL26567184 0.81 KDM4C (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17442671 0.80 KDM4D (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1647272 0.79 CYP1A2 (0.61) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22637811 0.78 CYP1A2 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22637814 0.78 CYP1A2 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29478781 0.78 CYP1A2 (0.42) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024043741-A1 AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 주식회사 레고켐 바이오사이언스 2024-02-29 WO disclosed
WO-2024043741-A1 AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 주식회사 레고켐 바이오사이언스 2024-02-29 WO disclosed
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, NR1I3, NR1H4 GABRP 3750/4885GABRD 2535/4885GABRA1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.